Recursion Pharmaceuticals (RXRX) Tax Provisions (2023 - 2026)
Recursion Pharmaceuticals' (RXRX) quarterly Tax Provisions came in at -$4.6 million in Q1 2026, down 2813.92% YoY from $169643.7 in Q1 2025, and down 23120.0% on a QoQ basis from $20000.0 in Q4 2025.
Recursion Pharmaceuticals (RXRX) Tax Provisions (2023 - 2026) Analysis & Trends
Recursion Pharmaceuticals (RXRX) has 4 years of Tax Provisions data on file, last reported at -$4.6 million in Q1 2026.
- Quarterly Tax Provisions fell 2813.92% year-over-year to -$4.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$4.6 million (down 803.55% YoY) and the FY2025 annual result came in at -$136000.0, up 87.93% from the prior year.
- Tax Provisions eased to -$4.6 million in Q1 2026, from $20000.0 in the prior quarter.
- In the past five years, Tax Provisions ranged from a high of $167000.0 in Q3 2024 to a low of -$4.6 million in Q1 2026.
- A 4-year average of -$1.1 million and a median of -$158000.0 in 2025 frame the typical range for Tax Provisions.
- Annual changes were most pronounced in 2025 — Tax Provisions surged 185.71% — and 2026, when it tumbled 2813.92%.
- Tracing RXRX's Tax Provisions over 4 years: stood at -$4.1 million in 2023, then surged by 100.17% to $7000.0 in 2024, then surged by 185.71% to $20000.0 in 2025, then plunged by 23120.0% to -$4.6 million in 2026.
- The last three Tax Provisions figures came in at -$4.6 million (Q1 2026), $20000.0 (Q4 2025), and $3000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 59.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 75.45 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 267.73 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.31 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.90 Mn |
| 10 | Recursion Pharmaceuticals | 1.69 Bn | 1.14 Bn | -3.82 Mn | -1,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1,000.00 |
| Mar 31, 2026 | -4.60 Mn |
| Dec 31, 2025 | 20,000.00 |
| Sep 30, 2025 | 3,000.00 |
| Mar 31, 2025 | -158,000.00 |
| Dec 31, 2024 | 7,000.00 |
| Sep 30, 2024 | 167,000.00 |
| Jun 30, 2024 | -523,000.00 |
| Mar 31, 2024 | -779,000.00 |
| Dec 31, 2023 | -4.06 Mn |